Jasco Pharmaceuticals, LLC

Covestro LLC

Microdose Therapeutx, Inc.

Carmen M Baldino

Justin L Caserta

Chee-Seng Lee

Stephane A Dumas

Yvonne L Flanders

Robert B Nicewonger

Shomir Ghosh

Zhongguo Wang

John Charles Warner

Frederick R Kearney

Justin Whitfield

Dan P Cook

Lazlo Varady

Thomas Andreas Waldbach

The present invention provides compositions comprising the reaction product of an aliphatic diisocyanate, and a reactive intermediate made from one selected from the group consisting of oxazolidinones, benzoic sulfimides (saccharins), 1H-indole-2,3-diones (isatins), succinamides, N-hydroxysuccinamides, 4-hydroxy-3-methoxybenzaldehydes (vanillins), &#x3b1;-ketoamides, piperazines, benzofuranones, 3,4-dihydroxycyclobut-3-ene-1,2-diones (squaric acids), squaric acid esters, &#x3b1;-ketoamides, anilines, and &#x3b1;-ketoamide, phenols. The aliphatic diisocyanate comprises one selected from the group consisting of isocyanurates, biurets, iminooxadiazine diones, urethanes, uretdiones, carbodiimides, and allophanates. The resulting compositions may be useful in producing coatings, adhesives, sealants, castings, composites and films having durability, color stability, high gloss, and chemical resistance properties similar to those made from polyurethane.

Alternative crosslinking mechanisms for polyurethane-based systems

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1&#x3b3;1, CK1&#x3b3;2, CK1&#x3b3;3, CK2, Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1&#x3b3;1, CK1&#x3b3;2, CK1&#x3b3;3, CK2, Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.

Aminopyrimidine kinase inhibitors

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), the TGF&#x3b2; pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), the TGF&#x3b2; pathway and/or the Wnt pathway.

Imidazole-2,4-dione inhibitors of casein kinase 1

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as cystic fibrosis and upper respiratory disorders.

Growing community of inventors

Woburn, MA, United States of America

Carmen M Baldino